Baseline characteristics of patients receiving 6 cycles (Group 1) versus more than 6 cycles (Group 2) of adjuvant temozolomide
| Characteristic . | Group 1 (6C) (N = 333) No (%) . | Group 2 (>6C) (N = 291) No (%) . | All (N = 624) No (%) . |
|---|---|---|---|
| Age, y* | |||
| <50 | 122 (36.6) | 99 (34.0) | 221 (35.4) |
| ≥50 | 211 (63.4) | 192 (66.0) | 403 (64.6) |
| Gender | |||
| Male | 191 (57.4) | 162 (55.7) | 353 (56.6) |
| Female | 142 (42.6) | 129 (44.3) | 271 (43.4) |
| WHO performance status* | |||
| 0 | 179 (53.8) | 214 (73.5) | 393 (63.0) |
| ≥1 | 154 (46.2) | 77 (26.5) | 231 (37.0) |
| Extent of resection* | |||
| Incomplete resection | 145 (43.5) | 142 (48.8) | 287 (46.0) |
| Complete resection | 186 (55.9) | 149 (51.2) | 335 (53.7) |
| Missing | 2 (0.6) | 0 (0.0) | 2 (0.3) |
| Corticosteroid therapy* | |||
| No | 189 (56.8) | 82 (28.2) | 271 (43.4) |
| Yes | 144 (43.2) | 209 (71.8) | 353 (56.6) |
| MGMT methylation status* | |||
| Unmethylated | 76 (22.8) | 132 (45.4) | 208 (33.3) |
| Methylated | 203 (61.0) | 139 (47.8) | 342 (54.8) |
| Unknown | 54 (16.2) | 20 (6.9) | 74 (11.9) |
| Characteristic . | Group 1 (6C) (N = 333) No (%) . | Group 2 (>6C) (N = 291) No (%) . | All (N = 624) No (%) . |
|---|---|---|---|
| Age, y* | |||
| <50 | 122 (36.6) | 99 (34.0) | 221 (35.4) |
| ≥50 | 211 (63.4) | 192 (66.0) | 403 (64.6) |
| Gender | |||
| Male | 191 (57.4) | 162 (55.7) | 353 (56.6) |
| Female | 142 (42.6) | 129 (44.3) | 271 (43.4) |
| WHO performance status* | |||
| 0 | 179 (53.8) | 214 (73.5) | 393 (63.0) |
| ≥1 | 154 (46.2) | 77 (26.5) | 231 (37.0) |
| Extent of resection* | |||
| Incomplete resection | 145 (43.5) | 142 (48.8) | 287 (46.0) |
| Complete resection | 186 (55.9) | 149 (51.2) | 335 (53.7) |
| Missing | 2 (0.6) | 0 (0.0) | 2 (0.3) |
| Corticosteroid therapy* | |||
| No | 189 (56.8) | 82 (28.2) | 271 (43.4) |
| Yes | 144 (43.2) | 209 (71.8) | 353 (56.6) |
| MGMT methylation status* | |||
| Unmethylated | 76 (22.8) | 132 (45.4) | 208 (33.3) |
| Methylated | 203 (61.0) | 139 (47.8) | 342 (54.8) |
| Unknown | 54 (16.2) | 20 (6.9) | 74 (11.9) |
*Enrollment (baseline) values.
Baseline characteristics of patients receiving 6 cycles (Group 1) versus more than 6 cycles (Group 2) of adjuvant temozolomide
| Characteristic . | Group 1 (6C) (N = 333) No (%) . | Group 2 (>6C) (N = 291) No (%) . | All (N = 624) No (%) . |
|---|---|---|---|
| Age, y* | |||
| <50 | 122 (36.6) | 99 (34.0) | 221 (35.4) |
| ≥50 | 211 (63.4) | 192 (66.0) | 403 (64.6) |
| Gender | |||
| Male | 191 (57.4) | 162 (55.7) | 353 (56.6) |
| Female | 142 (42.6) | 129 (44.3) | 271 (43.4) |
| WHO performance status* | |||
| 0 | 179 (53.8) | 214 (73.5) | 393 (63.0) |
| ≥1 | 154 (46.2) | 77 (26.5) | 231 (37.0) |
| Extent of resection* | |||
| Incomplete resection | 145 (43.5) | 142 (48.8) | 287 (46.0) |
| Complete resection | 186 (55.9) | 149 (51.2) | 335 (53.7) |
| Missing | 2 (0.6) | 0 (0.0) | 2 (0.3) |
| Corticosteroid therapy* | |||
| No | 189 (56.8) | 82 (28.2) | 271 (43.4) |
| Yes | 144 (43.2) | 209 (71.8) | 353 (56.6) |
| MGMT methylation status* | |||
| Unmethylated | 76 (22.8) | 132 (45.4) | 208 (33.3) |
| Methylated | 203 (61.0) | 139 (47.8) | 342 (54.8) |
| Unknown | 54 (16.2) | 20 (6.9) | 74 (11.9) |
| Characteristic . | Group 1 (6C) (N = 333) No (%) . | Group 2 (>6C) (N = 291) No (%) . | All (N = 624) No (%) . |
|---|---|---|---|
| Age, y* | |||
| <50 | 122 (36.6) | 99 (34.0) | 221 (35.4) |
| ≥50 | 211 (63.4) | 192 (66.0) | 403 (64.6) |
| Gender | |||
| Male | 191 (57.4) | 162 (55.7) | 353 (56.6) |
| Female | 142 (42.6) | 129 (44.3) | 271 (43.4) |
| WHO performance status* | |||
| 0 | 179 (53.8) | 214 (73.5) | 393 (63.0) |
| ≥1 | 154 (46.2) | 77 (26.5) | 231 (37.0) |
| Extent of resection* | |||
| Incomplete resection | 145 (43.5) | 142 (48.8) | 287 (46.0) |
| Complete resection | 186 (55.9) | 149 (51.2) | 335 (53.7) |
| Missing | 2 (0.6) | 0 (0.0) | 2 (0.3) |
| Corticosteroid therapy* | |||
| No | 189 (56.8) | 82 (28.2) | 271 (43.4) |
| Yes | 144 (43.2) | 209 (71.8) | 353 (56.6) |
| MGMT methylation status* | |||
| Unmethylated | 76 (22.8) | 132 (45.4) | 208 (33.3) |
| Methylated | 203 (61.0) | 139 (47.8) | 342 (54.8) |
| Unknown | 54 (16.2) | 20 (6.9) | 74 (11.9) |
*Enrollment (baseline) values.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
